Jim Cramer goes through a lightning round of callers and quickly gives his take on various caller stocks.
CNBC’s Meg Tirrell discusses the surge in biotech and pharmaceuticals following Trump’s victory, as well as what investors expect from here.
US Senator Bernie Sanders tweeted about the price of Eli Lilly's Humalog insulin, sending the company's stock down more than 1 percent.
CNBC's Meg Tirrell reports the latest news in pharma, including Novartis under pressure, and Merck's FDA drug approval.
Jim Cramer quickly provided his opinion on various stocks, including this one that left a sour taste from cutting the dividend.
CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.
Sen. Bernie Sanders and Rep. Elijah Cummings request details after Ariad repeatedly raised the price of its drug.
CNBC's Meg Tirrell reports the latest on a tweet sent by Sen. Bernie Sanders about Ariad Pharmaceuticals' cancer drug pricing.
CNBC's Meg Tirrell reports the latest on the controversy surrounding the California Drug Price Relief Act including the Bernie Sanders' support for the proposition.
Ariad Pharmaceuticals plunged as much as 15 percent after Sen. Bernie Sanders criticized the price of the company's leukemia drug.
CNBC's Meg Tirrell reports the latest details surrounding Martin Shkreli and his appearance back in court today facing fraud charges.
Jim Cramer rattles off his take on caller favorite stocks, including master limited partnerships like Kinder Morgan.
Michael Yee, RBC Capital Markets biotech analyst, shares his take on big biotech movers including Mylan, Tesaro and more.
Ariad Pharmaceuticals President and CEO Paris Panayiotopoulos, discusses patient response to cancer treatment Brigatinib.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
Michael Yee, BioTech Analyst at RBC Capital Markets, discusses the bio-pharma world's ASCO conference and which players to watch in the sector.
CNBC's Meg Tirrell reports on what to expect out of the ASCO conference and looks at Kensho data to see which companies have historically performed well in the space.
CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
CNBC's Meg Tirrell reports all the latest news in biotech. The Fast Money panel weighs in.
The "Halftime Report" traders give their top trades for the second half of the trading day.